• 1
    Smalley S. B., Moertel C. G., Hilton J. F., Weiland L. H., Wieand H. S., Adson M. A., et al. Hepatoma in the non-cirrhotic liver. Cancer 1988; 62: 141424.
  • 2
    Friedman M. Primary hepatocellular carcinoma: present results and future prospects. Int J Radiat Oncol Biol Phys 1983; 9: 184150.
  • 3
    Moertel C. G. Medical management of liver cancer. In: SchiffL., SchiffE., editors. Diseases of the liver. Philadelphia: JB Lippincott, 1982: 104884.
  • 4
    Olweny C. H., Toya T., Katongole-Mbidof F., Mugerwa J., Kyalwazi S. K., Cohen N. Treatment of hepatocellular carcinoma with Adriamycin. Cancer 1975; 36: 12507.
  • 5
    Vogel C. L., Bayley A. C., Brooker R. J., Anthony P. P., Ziegler J. R. A phase II study of Adriamycin NSC (123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer. 1977; 39: 19239.
  • 6
    Ihde D. C., Kane R. C., Cohen M. H., McIntire K. R. and Minna J. D. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 1977; 61: 13857.
  • 7
    Falkson G., Moertel C. G., Lavin P., Pretorius F. J., Carbone P. P. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978; 42: 214956.
  • 8
    Johnson P. J., Williams R., Thomas H., Sherlock S., Murry-Lyon I. M. Induction of remission in hepatocellular carcinoma with Adriamycin. Lancet 1978; 1: 10059.
  • 9
    Dushieko G. M., Kassianides C., Song E., Pitcher L., Ryff J. C., Kew M. C. Loss of hepatitis B surface antigen in three controlled trials of recombinant alpha interferon. J Med Virol 1987; 21: 120A.
  • 10
    Hoofnagle J. H., Peters M., Mullen K. D., Avigan M. I., Park Y., Waggoner J. G., et al. Randomized controlled trial of a 4-month course of recombinant human alpha interferon in patients with chronic type B hepatitis. Hepatology 1985; 5: 1033.
  • 11
    Chakraborty P. R., Ruiz-Opazo N., Shouval D., Shafritz D. A. Identification of integrated hepatitis B virus DNA and expression of viral RNA in HBSAG-producing human hepatocellular carcinoma cell line. Nature 1980; 286: 5313.
  • 12
    Sachs E., Di-Bisceglie A. M., Dusheiko G. M., Song E., Lyons S. F., Schoub B. D. Treatment of hepatocellular carcinoma with recombinant interferon: a pilot study. Br J Cancer 1985; 52: 1059.
  • 13
    The Gastrointestinal Tumor Study Group. A prospective trial of recombinant interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. Cancer 1990; 66: 1359.
  • 14
    Lai C. L., Wu P. C., Lok A. S. F., Arnold M., Lin H. J., Hui W. M., et al. Recombinant leukocyte A interferon versus Adriamycin in hepatocellular carcinoma: a randomized trial. Hepatology 1984; 4: 1015.
  • 15
    Slater L. M., Wetzel M. N., Cesario T. Combined interferon antimetabolite therapy of murine L1210 leukemia. Cancer 1981; 48: 59.
  • 16
    Gressler J., Maury C., Tovey M. Interferon and murine leukemia: VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice. Int J Cancer 1976; 17: 64751.
  • 17
    Chirigos M. A., Pearson J. W. Cure of murine leukemia with drug and interferon treatment. J Natl Cancer Inst 1973; 51: 13678.
  • 18
    Balkwill F. R., Moodie E. M. Positive interactions between human interferon and cyclophosphamide or Adriamycin in a human tumor model system. Cancer Res 1984; 44: 9048.
  • 19
    Morris L., Spiegel R. In vitro synergistic effect of recombinant human interferon alpha 2 (rIFN-a2) and Adriamycin (ADR) in a human Burkitt's lymphoma. Proc Am Assoc Cancer Res 1984; 25: 318.
  • 20
    Welander C., Gaines J., Homesley H., Rudnick S. In vitro synergistic effect of recombinant human interferon alpha (rIFL ∥2) and doxorubicin on human tumor cell lines. Proc Am Soc Clin Oncol 1983; 2: 42.
  • 21
    Creagan E. T., Long H. J., Frytak S., Moertel C. G. Recombinant leukocyte A interferon with doxorubicin: a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer 1988; 62: 47983.